Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio (NASDAQ:PASG) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $21.00 price target on the stock.